United States

People: Ablynx NV (ABLX.BR)

ABLX.BR on Brussels Stock Exchange

3:33am EST
Change (% chg)

€-0.02 (-0.16%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Moukheibir, Catherine 

Ms. Catherine Moukheibir is Independent Director of Ablynx NV. She has been in C-level positions in several European biotech companies after an initial career in strategy consulting and investment banking in Boston and London. Her particular experience lies in aligning corporate and financial strategy appropriate to various stages of a biotech’s development, on the continuum from venture capital funding to public market or M&A. She is currently a non-executive Board member of Creabilis and a Board observer at Zealand Pharma. She is also a member of the three-person management board at Innate Pharma where she is responsible for financial and corporate strategy. Catherine Moukheibir holds an MBA from Yale University.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --